BLOG

BLOG

2025-12-02

News Update Immorna Biotechnology’s Acne Therapeutic mRNA Vaccine JCXH-401 Receives US FDA Clearance to Initiate Clinical Trial

(Hangzhou, China, November 29, 2025) – Immorna Biotechnology, a biotechnology company focused on mRNA technology platforms, today announced that its investigational bivalent therapeutic mRNA vaccine candidate, JCXH-401, for the treatment of acne vulgaris, has received clearance from the United States Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1/2 clinical trial.
More +

2025-06-12

News Update Immorna Biotherapeutics Develops Next-Generation Influenza/COVID-19 Combination mRNA Vaccine Featuring Enhanced Immunogenicity of B Influenza Antigens

The development of the mRNA-based seasonal influenza vaccines remains challenging, in part because of the relatively low immunogenicity of influenza B hemagglutinin (HA) antigens.
More +

2025-03-30

News Update Immorna Biotherapeutics Announces First Clinical Administration of JCXH-213, a Breakthrough mRNA-based In Vivo CAR Therapy

Immorna Biotherapeutics today announced the successful dosing of the first patient in its clinical study of JCXH-213, an innovative in vivo Chimeric Antigen Receptor (CAR) therapy. This milestone represents the world’s first human application of a messenger RNA (mRNA)-lipid nanoparticle (LNP)-based in vivo CAR therapy.
More +

2024-08-26

News Update Immorna Receives Grant from Bill & Melinda Gates Foundation to Support Its mRNA RSV Vaccine Clinical Development

Research Triangle Park, NC Aug 14, 2024 – Immorna Biotherapeutics Inc. (Immorna) today announces that it has received a grant to support the clinical development of JCXH-108 from the Bill & Melinda Gates Foundation (the foundation).
More +

2024-07-09

News Update Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors

MORRISVILLE, N.C., July 8, 2024 /PRNewswire/ -- Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for JCXH-211 intravenous (IV), a novel, first-in-class self-replicating mRNA (srRNA) encoding the engineered human interleukin (IL)-12 protein.
More +

2024-06-06

News Update Immorna Biotherapeutics Presents Clinical Data for JCXH-211, a Self-Replicating RNA Encoding the Human IL-12, at ASCO 2024

Immorna Biotherapeutics Presents Clinical Data for JCXH-211, a Self-Replicating RNA Encoding the Human IL-12, at ASCO 2024
More +
< 123 >

Business license

Statement

SEO